Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease.

Department of Genome Sciences, University of Washington, Seattle, WA 98195, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 12/2011; 109(2):594-9. DOI: 10.1073/pnas.1116053109
Source: PubMed

ABSTRACT The human microbiome plays a key role in a wide range of host-related processes and has a profound effect on human health. Comparative analyses of the human microbiome have revealed substantial variation in species and gene composition associated with a variety of disease states but may fall short of providing a comprehensive understanding of the impact of this variation on the community and on the host. Here, we introduce a metagenomic systems biology computational framework, integrating metagenomic data with an in silico systems-level analysis of metabolic networks. Focusing on the gut microbiome, we analyze fecal metagenomic data from 124 unrelated individuals, as well as six monozygotic twin pairs and their mothers, and generate community-level metabolic networks of the microbiome. Placing variations in gene abundance in the context of these networks, we identify both gene-level and network-level topological differences associated with obesity and inflammatory bowel disease (IBD). We show that genes associated with either of these host states tend to be located at the periphery of the metabolic network and are enriched for topologically derived metabolic "inputs." These findings may indicate that lean and obese microbiomes differ primarily in their interface with the host and in the way they interact with host metabolism. We further demonstrate that obese microbiomes are less modular, a hallmark of adaptation to low-diversity environments. We additionally link these topological variations to community species composition. The system-level approach presented here lays the foundation for a unique framework for studying the human microbiome, its organization, and its impact on human health.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Functional metagenomic analyses commonly involve a normalization step, where measured levels of genes or pathways are converted into relative abundances. Here, we demonstrate that this normalization scheme introduces marked biases both across and within human microbiome samples, and identify sample- and gene-specific properties that contribute to these biases. We introduce an alternative normalization paradigm, MUSiCC, which combines universal single-copy genes with machine learning methods to correct these biases and to obtain an accurate and biologically meaningful measure of gene abundances. Finally, we demonstrate that MUSiCC significantly improves downstream discovery of functional shifts in the microbiome. MUSiCC is available at Electronic supplementary material The online version of this article (doi:10.1186/s13059-015-0610-8) contains supplementary material, which is available to authorized users.
    Genome Biology 12/2015; 16(1). DOI:10.1186/s13059-015-0610-8 · 10.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Average genome size is an important, yet often overlooked, property of microbial communities. We developed MicrobeCensus to rapidly and accurately estimate average genome size from shotgun metagenomic data and applied our tool to 1,352 human microbiome samples. We found that average genome size differs significantly within and between body sites and tracks with major functional and taxonomic differences. In the gut, average genome size is positively correlated with the abundance of Bacteroides and genes related to carbohydrate metabolism. Importantly, we found that average genome size variation can bias comparative analyses, and that normalization improves detection of differentially abundant genes.
    Genome biology 01/2015; 16(1):51. DOI:10.1186/s13059-015-0611-7 · 10.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The objectives of this report are to: ƒ analyse and map out the future development of BMI towards ultimate clinical utility such that it fulfils stakeholder needs (researchers, clinicians, health system providers, patients, industry and regulatory authorities), while paying attention to the ethical and security considerations, ƒ present BMI approaches that can help the ‘translation’ of biomedical research results into clinical practice, ƒ present methods of integration and extraction of data from biomedical research and healthcare practice in novel ways.

Full-text (2 Sources)

Available from
Jun 3, 2014